Physician profile
Rajeev Sharma
NPI 1174757652
$4,521.82
in general payments reported to CMS, 2019-2025
14 companies · $76.95 in 2025
The $76.95 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2021: $13.16 · 2022: $2,654 · 2023: $1,439 · 2024: $193 · 2025: $76.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,407 · Food and Beverage: $302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,406.94 |
| Food and Beverage | $301.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| One Lambda, INC. | $2,622.60 | 2022 | |
| Transmedics, INC. | $1,406.94 | 2023 | Organ Care System |
| Sanofi-Aventis U.S. LLC | $116.84 | 2024 | |
| Veloxis Pharmaceuticals, INC. | $79.28 | 2019 | |
| Vanda Pharmaceuticals INC. | $70.38 | 2021-2024 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $35.49 | 2024 | Austedo Xr, Uzedy |
| Mannkind Corporation | $30.34 | 2023-2024 | Afrezza |
| Insulet Corporation | $27.92 | 2025 | Omnipod |
| Tandem Diabetes Care, INC. | $25.59 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| E.R. Squibb & Sons, L.L.C. | $23.56 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $23.55 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.44 | 2025 | Livtencity |
| Vyera Pharmaceuticals, LLC | $19.65 | 2019 | |
| Amneal Pharmaceuticals LLC | $16.24 | 2023 | Unithroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajeev Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.